Q-omics provides the consensus-scored MED25 profile across patient tissues and cancer cell-line models. MED25 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MED25 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, MED25 protein abundance shows 22,310 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where MED25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED25 survival associations across molecular data types. MED25 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED25 RNA expression–survival associations across cancer types. High MED25 expression shows unfavorable associations in KIRC, LIHC, LGG and LUSC, but favorable associations in HNSC and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MED25 RNA expression.
This table summarizes MED25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MED25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED25 shows higher tumor expression in COAD, STAD, KIRP, LIHC, HNSC and BRCA. The COAD box plot shows higher MED25 RNA expression in tumor versus normal tissue (log2 FC = +0.984, t-test p < 0.001).
This table shows molecular features associated with MED25 in patient tissues and cancer cell lines. In patient samples, MED25 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
